Bagatell, Rochelle

Using electronic medical record data to report laboratory adverse events

Miller, T. P., Li, Y., Getz, K. D., Dudley, J., Burrows, E., Pennington, J., Ibrahimova, A., Fisher, B. T., Bagatell, R., Seif, A. E., et al. (2017) · British Journal of Haematology

Pharmacovigilance and Adverse Drug ReactionsElectronic Health Records Systems

Cited by 47

Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors: Phase 1 Trial of EZN2208

Norris, R. E., Shusterman, S., Gore, L., Muscal, J. A., Macy, M. E., Fox, E., Berkowitz, N., Buchbinder, A., & Bagatell, R. (2014) · Pediatric Blood & Cancer

Cancer therapeutics and mechanismsPharmaceutical studies and practices

Cited by 38

Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.

Shulman, D. S., Klega, K. S., Chen, N., Gohn, E., Henry, D., Choy, E., Cash, T., Schultz, K. A. P., Mascarenhas, L., Bagatell, R., et al. (2024) · Journal of Clinical Oncology

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 8

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Church, A. J., Corson, L., Kao, P.-C., Imamovic-Tuco, A., Kang, W., Pinto, N. R., Maese, L., Laetsch, T. W., Kim, A., Colace, S., et al. (2021) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 2